BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail 2013;6:862-8. [PMID: 23861505 DOI: 10.1161/CIRCHEARTFAILURE.113.000394] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Murakami N, Tanno M, Kokubu N, Nishida J, Nagano N, Ohnishi H, Akasaka H, Miki T, Tsuchihashi K, Miura T. Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data. Open Heart 2017;4:e000573. [PMID: 28123767 DOI: 10.1136/openhrt-2016-000573] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
2 Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF; NHLBI Heart Failure Clinical Research Network. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation 2015;131:1763-71. [PMID: 25986447 DOI: 10.1161/CIRCULATIONAHA.114.014536] [Cited by in Crossref: 159] [Cited by in F6Publishing: 55] [Article Influence: 22.7] [Reference Citation Analysis]
3 Wojciechowska C, Jacheć W, Romuk E, Ciszek A, Bodnar P, Chwalba T, Waliczek M, Gąsior M, Rozentryt P. Serum Sulfhydryl Groups, Malondialdehyde, Uric Acid, and Bilirubin as Predictors of Adverse Outcome in Heart Failure Patients due to Ischemic or Nonischemic Cardiomyopathy. Oxid Med Cell Longev 2021;2021:6693405. [PMID: 33936385 DOI: 10.1155/2021/6693405] [Reference Citation Analysis]
4 Bonsu KO, Owusu IK, Buabeng KO, Reidpath DD, Kadirvelu A. Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag 2016;12:887-906. [PMID: 27350750 DOI: 10.2147/TCRM.S106065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
5 Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med 2015;128:653.e7-653.e16. [PMID: 25660249 DOI: 10.1016/j.amjmed.2015.01.013] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 7.6] [Reference Citation Analysis]
6 Cervantes Gracia K, Llanas-Cornejo D, Husi H. CVD and Oxidative Stress. J Clin Med 2017;6:E22. [PMID: 28230726 DOI: 10.3390/jcm6020022] [Cited by in Crossref: 120] [Cited by in F6Publishing: 86] [Article Influence: 24.0] [Reference Citation Analysis]
7 Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. Circulation 2018;138:1116-26. [PMID: 29899013 DOI: 10.1161/CIRCULATIONAHA.118.033992] [Cited by in Crossref: 56] [Cited by in F6Publishing: 13] [Article Influence: 18.7] [Reference Citation Analysis]
8 Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, Young R, Shah N, Samuel M, Sheikh N, Mucksavage ML, Shah O, Li J, Morley M, Laser A, Mallick NH, Zaman KS, Ishaq M, Rasheed SZ, Memon FU, Ahmed F, Hanif B, Lakhani MS, Fahim M, Ishaq M, Shardha NK, Ahmed N, Mahmood K, Iqbal W, Akhtar S, Raheel R, O'Donnell CJ, Hengstenberg C, März W, Kathiresan S, Samani N, Goel A, Hopewell JC, Chambers J, Cheng YC, Sharma P, Yang Q, Rosand J, Boncoraglio GB, Kazmi SU, Hakonarson H, Köttgen A, Kalogeropoulos A, Frossard P, Kamal A, Dichgans M, Cappola T, Reilly MP, Danesh J, Rader DJ, Voight BF, Saleheen D. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol 2016;67:407-16. [PMID: 26821629 DOI: 10.1016/j.jacc.2015.10.086] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 14.7] [Reference Citation Analysis]
9 Halkar M, Tang WH. Incorporating common biomarkers into the clinical management of heart failure. Curr Heart Fail Rep 2013;10:450-7. [PMID: 24085636 DOI: 10.1007/s11897-013-0165-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Jee Y, Jeon C, Sull JW, Go E, Cho SK. Association between smoking and gout: a meta-analysis. Clin Rheumatol 2018;37:1895-902. [PMID: 29696438 DOI: 10.1007/s10067-018-4118-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Joseph J, Giczewska A, Alhanti B, Cheema AK, Handy DE, Mann DL, Loscalzo J, Givertz MM. Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. J Physiol Biochem 2021;77:295-304. [PMID: 33595776 DOI: 10.1007/s13105-021-00797-x] [Reference Citation Analysis]